Key Insights

Highlights

Treatment Research

3 treatments under study, led by Ibrexafungerp

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05178862Phase 3Terminated

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Showing all 1 trials

Research Network

Common Treatments

  • Ibrexafungerp1
  • Echinocandin1
  • Fluconazole1

Active Sponsors

  • Scynexis, Inc.1

Top Investigators

Related Conditions

  • Candidemia1
  • Candidiasis Invasive1

Activity Timeline